Abstract Regression of established tumors can be induced by adoptive immunotherapy (AIT) with tumor draining lymph node (DLN) lymphocytes activated with bryostatin and ionomycin (B/I). We hypothesized that B/Iactivated T cells cultured in IL-7 + IL-15 might proliferate and survive in culture better than cells cultured in IL-2, and that these cells would have equal or greater anti-tumor activity in vivo. Tumor antigen-sensitized DLN lymphocytes from either wild-type or T cell receptor transgenic mice were harvested, activated with B/I, and expanded in culture with either IL-2, IL-7 + IL-15 or a regimen of alternating cytokines. Cell yields, proliferation, apoptosis, phenotypes, and in vitro responses to tumor antigen were compared for cells grown in diVerent cytokines. These T cells were also tested for anti-tumor activity against mela- 
Introduction
The immune system, and particularly CD8+ T lymphocytes, can potentially be harvested from tumor-bearing hosts and used to eliminate cancers, as demonstrated by studies of numerous animal models and a few clinical trials [6, 9-12, 32, 34, 51] . Monoclonal antibodies, cytokines, and pharmacological methods have been used successfully in mouse models to activate lymphocytes isolated from tumors or tumor draining lymph nodes (DLN), which can then be adoptively transferred to tumor bearing hosts and cause regression of established tumors [6, 9-11, 20, 35, 36, 39, 52] . Adoptive immunotherapy (AIT), or the adoptive transfer of antigen-sensitized T cells activated and/or expanded in vitro continues to receive attention [1, 13, 22, 35, [44] [45] [46] 50] .
The success of AIT relies on manipulation of a host's lymphocytes to produce large numbers of tumor-speciWc cells that are optimized in eVector functions. AIT circumvents the in vivo constraints that inXuence the magnitude and avidity of T cell responses against tumor, allowing the generation and activation of lymphocytes away from the suppressive tumor environment. In addition, it allows for the treatment of the host before reintroduction of the selected cells, thereby providing the optimal environment for anti-tumor responses.
We have shown that in vitro treatment of tumor antigensensitized draining lymph node (DLN) cells with bryostatin and ionomycin (B/I) selectively activates sensitized T lymphocytes that can induce regression of several diVerent murine tumors, either primary or metastatic, and can confer long-term resistance to re-challenge [13, [44] [45] [46] . Bryostatin 1 is a macrocyclic lactone derived from Bugula neritina, a marine invertebrate. Bryostatin activates protein kinase C and ionomycin increases intracellular calcium [4, 7, 24, 38] . Together, these mimic signaling through the CD3/TcR complex and lead to activation and proliferation of T cells [4] . In the 4T1 mammary carcinoma model, we have previously shown that B/I selectively activates CD62L¡ or sensitized T cells and that the anti-tumor activity resides in the CD62L¡ fraction of lymphocytes obtained from donor lymph nodes; only the CD62L¡ subset proliferates after B/ I activation and has anti-tumor activity [8] .
Although it has been routine in our lab and others to use the T cell growth factor interleukin-2 (IL-2) to stimulate the proliferation of anti-tumor T cells in culture, IL-2 expansion may lead to the induction of regulatory T cells (T regs) and cause activation-induced cell death in T cells [14, 21, 37, 40, 48, 49, 53] . Other cytokines that stimulate T cell growth, via a gamma chain shared with the IL-2 receptor complex, may have a number of important advantages. In particular, IL-7 and IL-15 support the proliferation and survival of T cells more eVectively than IL-2. Unlike IL-2, IL-7 and IL-15 do not cause activation-induced cell death, nor are they critical for the maintenance of T regs [14, 37, 48, 49] . Moreover, these alternate gamma chain cytokines have been found to support preferential diVerentiation of CD8+ T cells toward a central memory (Tcm) phenotype, which some have suggested may be more eVective at inducing tumor regression than the eVector cells that are more likely to develop when lymphocytes are grown in IL-2 [26, 27] . Indeed, IL-15 has been shown to be as eVective or even somewhat more eVective than IL-2 for the production and support of T cells used for AIT against melanoma and other tumors [2, 5, 26] . For these reasons, we hypothesized that growth of B/I-activated T cells in alternate gamma chain cytokines might stimulate greater expansion of T cells capable of mediating tumor regression and of establishing T cell memory in the adoptive host than similarly activated T cells grown in IL-2. In this report, we show that the combination of IL-7 and IL-15 yields many times the number of T cells activated with B/I compared to our standard optimal dose of IL-2, and that IL-7/15-cultured cells are as eVective or more eVective than similar cells grown in IL-2 at mediating tumor regression in vivo, without the addition of exogenous cytokines or vaccines.
Methods

Mice
Virus-free C57Bl/6 mice (Charles River Laboratories, Cambridge, MA) were used between 8 and 12 weeks of age, caged in groups of six or fewer, and provided food and water ad libitum. Nude athymic BALB/c mice (National Cancer Institute, Bethesda, MD) were used to produce hybridoma ascites. T cell receptor (TcR) transgenic pmel-1 mice, with TcR speciWc for the peptide KVPRNQDWL derived from gp100 bound to class I of H-2 b , were produced from breeding pairs obtained from Jackson Laboratories (Bar Harbor, Maine). OT-1 TcR transgenic mice with TcR speciWc for SIINFEKL peptide of ovalbumin were also produced from breeding pairs from Jackson Laboratories. All guidelines of the Virginia Commonwealth University Institutional Animal Care and Use Committee, which conform to the American Association for Accreditation of Laboratory Animal Care and the US Department of Agriculture recommendations for the care and humane experimental use of animals, were followed.
Tumor cell lines and hybridomas B16-GMCSF and B16-F10 melanoma tumor cell lines were kindly provided by Dr. Richard Dutton (Trudeau Institute, Saranac Lake, NY) and by Dr. Rodney Prell (Cell Genesys, Inc., South San Francisco, CA), respectively. Melanoma cells were cultured in complete RPMI 1640 with 10% heatinactivated fetal calf serum, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 0.075% sodium bicarbonate, 2 mM L-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, 10 mM Hepes buVer, and 5 £ 10 ¡5 M 2-mercaptoethanol (Sigma, St Louis, MO). Tumor cells were harvested for inoculation of mice with 0.05% trypsin-EDTA (Invitrogen), washed twice with 1£ PBS and resuspended in 1£ PBS. All cells were incubated in 250 ml T-Xasks (PGC, Gaithersburg, MD) at 37°C in humidiWed air with 5% CO2.
Draining lymph node sensitization
Wild-type C57Bl/6 or pmel-1 mice were inoculated with 1 £ 10 6 B16-GMCSF cells. Ten days after footpad vaccination, popliteal tumor draining lymph nodes (tDLN) were harvested under sterile conditions. Lymphocyte activation and in vitro expansion DLN's or spleens were harvested and dispersed into single cell suspensions in complete RPMI media at 1 £ 10 6 cells/ ml. Splenic mononuclear cells were enriched by Ficoll density gradient centrifugation and erythrocytes were removed by suspension in ammonium chloride. The cells were then activated by incubation with 5 nM bryostatin 1 (provided by the National Cancer Institute, Bethesda, MD) and 1 M ionomycin (Calbiochem, San Diego, CA) (B/I), and 80 U/ ml of rIL-2 (Chiron, Emeryville, CA) at 37°C for 18 h. Cells were washed three times with warm complete RPMI and resuspended at 1-2 £ 10 6 cells/ml with 40 U/ml of rIL-2. The cells were allowed to proliferate in culture for an additional 7-14 days and were split every 2-3 days in order to maintain 1-2 £ 
Flow cytometry
Cells isolated from tDLN and expanded as described above were stained with a panel of antibodies and analyzed by dual color Xow cytometry for surface marker expression on an ELITE Beckman Coulter Xow cytometer. Fluorescently labeled Abs directed against the following markers were obtained from Pharmingen (San Diego, CA): Pan-DX5(DX5), CD4 (GK1.5), CD8 (53-6.7), CD44 (IM7), CD62L (MEL-14), and CD69 (H1.2F3). Appropriate isotype controls were used in all cases.
Assessment of lymphocyte apoptosis
Apoptosis was determined using the standard Annexin V-FITC Apoptosis Detection kit (BD Biosciences Pharmingen, San Diego, CA). B/I-activated and expanded DLN cells were washed twice with 1£ PBS and resuspended in 1£ binding buVer at a 200,000 cells/100 l and double stained for Annexin V and propidium iodide (PI). Unstained cells were used as negative controls and staining with Annexin V alone or PI alone was used as single color positive controls. 20,000 cells per sample were analyzed. Annexin V+/PI¡ cells were considered early apoptotic cells, Annexin V+/PI+ cells were considered late apoptotic cells, and double negative cells were considered viable.
Enumeration of melanoma lung metastases
In all AIT experiments mice were euthanized by CO 2 inhalation at times shown (about 3 weeks after tumor cell infusions) and lungs were removed, Wxed in 10% formaldehyde, and black lung nodules were counted under a dissecting microscope, as previously described [30] .
Cytokine release assays
Interferon-(IFN-) release in supernatant Xuids from tumor sensitized, fresh or B/I-activated and expanded lymphocytes in response to stimulation with irradiated B16 melanoma cells or peptide-pulsed spleen cells for 24 h was assayed using ELISA assays from Pharmingen (San Diego, CA).
Isolation of RNA and RT-PCR Total RNA was isolated from cells using Trizol (InVitrogen, Carlsbad, CA). Samples were treated with RQ DNase (Promega, Madison, WI) according to the manufacturer's protocol. About 4 g of RNA was used in the RT-PCR reaction, using BioScript Rnase H Minus RT (Bioline, Randolph, MA) according to the manufacturers protocol and oligo dT primer. AmpliWcation of actin was used as an internal control. Granzyme B RNA was detected according to the procedures of Lian et al. [29] , FasL RNA according to the procedures of Hallaas et al. [19] , and Foxp3 as described by Fontenot [15] . RT-PCR products were separated on a 0.8% agarose gel and visualized with ethidium bromide.
Statistical analysis
In vivo experiments included at least six mice per group and were repeated at least twice. DiVerences in pulmonary metastases were assessed by analysis of variance (Wilcoxonrank sum test) using JMPIN software (SAS Institute Inc., Cary, NC). Results are presented as the means § standard error (SE) in each treatment group. In vitro assays were repeated at least twice. A P < 0.05 was used throughout to determine signiWcant diVerences.
Results
Comparative analysis of T cell expansion and in vitro anti-tumor responses using diVerent gamma chain cytokine regimens Wild-type C57Bl/6 mice were inoculated with B16-GMCSF in the footpad, and popliteal tDLN were harvested and activated with B/I and expanded in either IL-2, IL-7/15 or an alternating regimen (IL-7/15 for 24 h, followed by IL-2 for 24 h, and then IL-7/15 for the remainder of the culture). The alternating regimen (IL-7/15-IL-2-IL-7/15) was based on observations with human PBL and the FVB 6 B16-GMCSF cells in the footpad. Ten days later ipsilateral popliteal DLNs were harvested and pulsed for 18 h at 1 £ 10 6 cells/ml in B (5 nM)/I (1 M) + IL-2 (80 U/ml) or B/I + IL-7/ 15 (10 ng/ml each) then expanded in IL-2 (40 U/ml) or IL-7/15 (10 ng/ ml each), respectively, or after being pulsed with B/I + IL-2, were cultured in alternating cytokines for times shown. Fold-expansion is based on viable cell counts on each day, compared to the number plated immediately after pulsing with B/I. b Pmel-1 mice were injected with 1 £ 10 6 B16-GMCSF cells in the footpad. Ten days later ipsilateral popliteal DLNs were harvested and pulsed for 18 h at 1 £ 10 6 cells/ml in B (5 nM)/I (1 M) + IL-2 (80 U/ml) or B/I + IL-7/15 (10 ng/ml each) then expanded in IL-2 (40 U/ml) or IL-7/15 (10 ng/ml each), respectively, or after being pulsed with B/I + IL-2, were cultured in alternating cytokines for times shown. Fold-expansion is based on viable cell counts on each day, compared to the number plated immediately after pulsing with B/I. c Pmel-1 mice were injected with irradiated C57Bl/6 splenocytes pulsed with gp100 peptide i.v., weekly £ 2. Ten days later splenic mononuclear cells were harvested and pulsed for 18 h at 1 £ 10 6 cells/ml in B (5 nM)/I (1 M) + IL-2 (80 U/ml) or B/ I + IL-7/15 (10 ng/ml each) then expanded in IL-2 (40 U/ml), IL-7/15 (10 ng/ml each), respectively for times shown. Fold-expansion is based on viable cell counts on each day, compared to the number plated immediately after pulsing with B/I. d Pmel-1 mice were injected with 1 £ 10 6 B16-GMCSF cells in the footpad. Ten days later ipsilateral popliteal DLNs were harvested and pulsed for 18 h at 1 £ 10 6 cells/ml in B (5 nM)/I (1 M) + IL-2 (80 U/ml) or B/I + IL-7/15 (10 ng/ml each), then cultured in microtiter well plates (at either 12,000 or 25,000 cells per well) in IL-2 (40 U/ml), IL-7/15 (10 ng/ml each) or alternating cytokines. On day 6, wells were pulsed with tritiated thymidine and harvested on glass Wber Wlters 24 h later and counted in a beta scintillation counter. Similar results were obtained on day 3 mouse model of breast carcinoma, indicating that after 1-2 days in IL-7/15, expression of IL-7 receptors dropped dramatically, and this was rapidly restored by 24 h in IL-2 (data not shown). As indicated in Fig. 1a , B16-sensitized lymph node cells from wild-type C57Bl/6 mice cultured in IL-7/15 or in alternating cytokines both grew at a much faster rate and for more prolonged periods (2 vs 1 week) than cells cultured in IL-2 alone. To make the relative eVects of alternate cytokine regimens more easily interpretable, TcR transgenic mice on a C57Bl/6 background were studied. B16-sensitized DLN cells from pmel-1 TcR transgenic mice (Fig. 1b) and splenic lymphocytes from pmel-1 mice sensitized with gp100 peptide (Fig. 1c ) grew more rapidly in IL-7/15 than in IL-2. We did not always see signiWcantly higher yields of cells with alternating cytokines versus IL-7/15 (as shown in Fig. 1a) , especially for pmel-1 cells. However, regardless of which cytokines were included in the B/I activation step, subsequent culture in IL-7/15 or alternating cytokines consistently resulted in much greater expansion of viable cells than in IL-2 in more than ten separate experiments, and was consistently 5-to 12-fold greater than in IL-2 alone for DLN cells. As shown in Fig. 1d , IL-7/15 or the alternating cytokine regimen induced greater proliferative activity, as assessed by tritiated thymidine uptake. Similar results were seen on days 3 and 6 of culture. In order to determine the mechanism(s) of the more rapid and prolonged growth of T cells in IL-7/15, we examined cells cultured in IL-2 or IL-7/15 for early and late apoptosis at various time points. As shown in Fig. 2 , the levels of early and late apoptotic cells increased progressively when cells were cultured in IL-2 and were much higher on days 6 and 8 than for cells cultured in IL-7/15. In repeat experiments, nearly 50% of cells cultured in IL-2 were apoptotic on day 6, versus only 16% of cells cultured in IL-7/15.
OT-1 mice received i.v. infusion of SIINFEKL-pulsed irradiated C57Bl/6 splenocytes. Spleen cells from these immunized mice were harvested, activated with B/I and then cultured with diVerent cytokines and cytokine combinations for 7 days. Again, expansion was much greater in IL-7/15 than in IL-2 (Wve-to ten-fold greater in diVerent experiments). RT-PCR analysis of T cells from each culture are shown in Fig. 3 , and show that cells cultured in IL-7 + IL-15 expressed much lower levels of Foxp3 than the same cells grown in IL-2. There was a modest reduction in perforin expression in cells cultured in IL-7/15, but there was no diVerence in Granzyme B expression. The phenotypes of cells obtained from cultures in diVerent cytokines and harvested on days 1, 3, and 7 after B/I activation are shown in Table 1 . Early in these cultures, similar proportions of CD4+ and CD8+ cells were seen in both IL-2 and IL-7/15 cultures. However, IL-7/15 induced an increase in the proportion of CD8+ cells and a much higher proportion of cells expressing CD62L by day 7 of culture compared to IL-2. CD69 was also expressed by a higher proportion of cells cultured in IL-7/15. In three separate experiments, in which dual staining was performed, the proportion of CD44+CD62L high cells was consistently higher for cells cultured in IL-7/15 (50-62%) than for cells cultured in IL-2 (20-42%) on days 6-8 of culture, as shown in Fig. 4 .
Wild-type C57Bl/6 lymphocytes harvested from cultures grown in IL-7/15 on day 5 secreted higher levels of IFNin response to B16 melanoma cells than those grown in IL-2 (Fig. 5a) . Moreover, cells harvested after 14 days in culture with IL-7/15 secreted even higher levels of IFN-. Cells cultured in IL-2 did not survive that long and so could not be compared at this time point. DLN cells from pmel-1 mice vaccinated with B16-GMCSF cells and tested immediately after harvest secreted IFN-in response to gp100 peptide or B16 melanoma cells (Fig. 5b) In an attempt to determine more clearly the relative potency of T cells grown in these alternate regimens, a cell doseresponse experiment was performed, as shown in Fig. 6b ). At each of the two lower cell doses (2 and 7.5 £ 10 6 ), there was a trend for IL-7/15 cultured cells to be more eVective, but comparisons of the number of metastases to mice treated with IL-2 cultured cells did not reach statistical signiWcance. However, at 15 £ 10 6 cells per mouse, IL-7/15 cultured cells were signiWcantly more eVective than IL-2 Three weeks later, these mice and untreated controls were challenged i.v. with B16 melanoma cells. As shown in Fig. 6c, d , the adoptively transferred lymphocytes conferred substantial protection against lung metastases, but IL-7/15-cultured cells and cells grown in alternating cytokines were again somewhat more eVective than cells grown in IL-2.
Discussion
These results demonstrate that culturing B/I-activated lymphocytes from tumor or tumor antigen-sensitized mice in IL-7 + IL-15 results in a much higher yield of viable cells with equal or greater activity against melanoma metastases in vivo than the same cells cultured in IL-2. This results from greater proliferation and greatly reduced apoptosis in culture. These results are consistent with those of KlebanoV et al. [26, 27] , who showed that culturing antigen-sensitized T cells in IL-15 prior to AIT produced greater numbers of cells in vivo than cells cultured in IL-2. However, they did not comment on the relative growth of cells in vitro in the two diVerent cytokines. In preliminary experiments using the 4T1 mammary carcinoma model (not shown here), we had found that culturing B/I-activated tumor antigensensitized lymphocytes in IL-7 or IL-15 alone produced expansion that was at most only 2-to 3-fold greater than with IL-2 alone (data not shown), but that culturing tumorsensitized DLN cells in the two cytokines combined produced dramatically increased expansion (5-to 10-fold) of DLN cells in culture. This led to the experiments shown here using the B16 melanoma model. The Wnding that IL-7 combined with IL-15 was markedly more eVective than IL-2 or either of the alternate cytokines alone is consistent with the suggestion made previously that, even though both IL-7 and IL-15 have roles in the maintenance and selfrenewal of memory precursors, eVector CD8+ T cells actually need both IL-7 and IL-15 for optimal proliferation and to become long-lived memory cells [23] . Carrio et al. [5] showed that IL-2 induced greater proliferation of CTL and higher levels of IFN-secretion than IL-7 or IL-15 alone. This diVerence resulted in part from the preferential selection of eVector T cells by IL-2 and selection of memory T cells by IL-7 and IL-15. Our data contrast with the data presented by Carrio et al.; we found that IL-7 or IL-15, and especially the combination of both IL-7 and IL-15, expands T cells to a much greater extent than IL-2. The contradictory results may be caused by a diVerence in the protocol used to produce activated T cells. Carrio et al. initially activated naïve T cells in vitro with splenocytes pulsed with speciWc peptide plus IL-2, while our protocol employs pharmacological activation with bryostatin-1 and ionomycin of T cells previously sensitized in vivo. The strength of signaling through the TcR pathway plays a role in prolonging T cell survival both in vitro and in vivo by regulating the capacity of primed T cells to respond to homeostatic cytokines, to survive cytokine withdrawal, and to accumulate in vivo [18, 28] . It is possible that T cell activation with B/I produces stronger and more prolonged TcR pathway signaling, which would increase the capacity of sensitized T cells to respond to homeostatic cytokines, like IL-7 and IL-15. This may also explain why we did not see as marked a diVerence among the regimens in T cell phenotypes, since it has been suggested that absence of antigen may contribute to diVerentiation toward central memory cells in the presence of IL-15 [41] . Interestingly, we also did not observe a shift away from IFNproduction which is supposed to be characteristic of the diVerentiation toward central memory cells and away from terminally diVerentiated eVector cells [16, 23] . In fact, we found that B/I-activated T cells grown in IL-7/15 had increased IFN-responses compared to cells grown in IL-2. Moreover, we did not observe signiWcant levels of IL-2 secretion in response to tumor cells or tumor antigen for any of the expansion groups (data not shown). Future studies will determine which T cells (e.g., CD62L+ or CD62L¡) are the main source of IFN-in each expansion protocol, using Xow cytometric analysis of surface markers and intracellular cytokine.
Melchionda et al. [33] showed that IL-7 and IL-15 were comparable to or better than IL-2 at expanding Ag sensitized CD8+ T cells when given as an adjuvant in vivo along (10 ng/ml each), then expanded in IL-2 (40 U/ml) or IL-7/15 (10 ng/ml each), respectively, or after being pulsed with B/I + IL-2, were cultured in alternating cytokines for times shown. Cells were harvested from cultures at times shown on x-axis. Cells were incubated with stimulants at a ratio of 10:1 in 24 well plates at a concentration of 2 £ 10 6 lymphocytes/ml. Supernatants were collected 24 h after exposure to stimulants and assayed for IFN-using the murine IFN-ELISA kit. Baseline refers to the response of cells immediately after harvest of DLN. IL-2-cultured cells were tested at 5 days, but did not survive long enough to be tested at 14 days. b, c B16-GMCSF sensitized DLNs from pmel-1 mice were harvested and pulsed for 18 h at 1 £ 10 6 cells/ml in B (5 nM)/I (1 M) + IL-2 (80 U/ml) or B/I + IL-7/ 15 (10 ng/ml each) then expanded in IL-2 (40 U/ml) or IL-7/15 (10 ng/ ml each), respectively, or after being pulsed with B/I + IL-2, were cultured in alternating cytokines for times shown. Samples were taken on days 0 (prior to B/I pulse, shown in b), 1, 3 (not shown), and 7 (shown in c) of expansion and stimulated with media alone (NIL), with irradiated splenocytes (IRR SPLEEN), or irradiated splenocytes pulsed with the speciWc peptide, gp100 (GP100) or with irradiated B16 melanoma cells. Cells were incubated with stimulants at a ratio of 10:1 in 24 well plates at a concentration of 2 £ 10 6 lymphocytes/ml. Supernatants were collected 24 h after exposure to stimulants and assayed for IFNusing the murine IFN-ELISA kit. Data are shown as the mean of duplicates § SD with immunization. There was, however, no additive or synergistic eVect when IL-7 and IL-15 were combined. In our in vitro B/I activation model, we have shown that the combination of IL-7 and IL-15 has an additive eVect on expansion, increasing T cell numbers 5-to 12-fold over IL-2. We found that this diVerence in expansion resulted partly from the protective roles of IL-7 and IL-15 against apoptosis [3, 25, 42, 43] . By day 6 of expansion, 40-50% of IL-2 expanded T cells were apoptotic. In contrast, only 15-18% of IL-7/15 expanded T cells were apoptotic. The greater rate of apoptosis in IL-2 expanded cells may be the result of IL-2 mediated activation-induced cell death [40, 47] . To strengthen this argument, future experiments should look for diVerences in expression levels of FasL and antiapoptotic molecules like Bcl-2 and Bcl-X L .
Although it has been shown that T cells grown in IL-15 persisted longer after adoptive transfer and provided better protection against tumor challenge than cells grown in IL-2, IL-15-expanded T cells were actually less eVective at inducing regression of established tumors in a model using OVA-transfected EL-4 [5, 41] . However, KlebanoV et al. [26, 27] found that IL-15-cultured pmel-1 cells were more eVective at inducing regression of established subcutaneous B16 melanomas than T cells cultured in IL-2. This was related to a shift towards a central memory phenotype, greater proliferation of IL-15 cultured cells in vivo and increased traYcking to lymphoid tissues. We did observe a moderate shift toward a greater number of CD62L+ cells when B/I-activated T cells were cultured in IL-7/15 versus IL-2, and the IL-7/15 cells were somewhat more eVective at inducing tumor regression than IL-2 cultured cells, but this diVerence was not as dramatic as the earlier results of KlebanoV et al. This could relate to a number of diVerences, including the use of antigen-sensitized versus naïve T cells, the use of B/I to re-activate the cells in vitro, treating pulmonary metastases rather than subcutaneous tumors, or the combined use of IL-7 and IL-15 instead of IL-15 alone. It seems likely that the ability of T cells to traYc to lymphoid organs, which is favored by the use of IL-15 and the Tcm phenotype, may not be as important for treatment of pulmonary metastases as it would be for subcutaneous solid tumors or for response to a vaccine. In addition, the successful regression of B16 melanoma tumors in the studies reported by KlebanoV was achieved by a complex regimen combining AIT with sublethal irradiation, vaccination with a recombinant virus encoding the target antigen and administration of exogenous cytokines. It has also been suggested that cells grown for short periods of time may be more eVective than cells cultured for several weeks, as the latter leads to more terminally diVerentiated cells [17] . In all of the AIT experiments shown here, we harvested cells from culture after 6-7 days, although IL-7/15 cultured cells were capable of growing much longer without needing an additional activation with B/I or antigen.
Preliminary studies have been reported with human PBL from melanoma patients vaccinated with a peptide tumor antigen to examine the relative merits of using alternate cytokines to expand T cells for AIT [31] . These studies did not show any consistent major diVerences in the yield or phenotypes of cells grown in IL-7, IL-15 or combinations compared to IL-2. This may not necessarily mean that results similar to what we are reporting here would not be achieved with human T cells, since this may depend on the source of cells, the prior sensitization and the method of in vitro activation. In addition, the concentration of IL-2 used in the reported human experiments was 300 versus 40-80 IU/ml (which we have found to be the optimal concentration for expansion of B/I-activated cells) in our experiments. This concentration also maintains antigen speciWcity more reliably than higher doses. We also used lower concentrations of IL-7 and IL-15 than were used in the human studies. Although we did not Wnd that IL-7/15-cultured cells were markedly more eVective than cells grown in IL-2 on a per cell basis, they were always as eVective or slightly more eVective in vivo. The major advantage of using the alternate or alternating cytokines appears to be the increased yield of viable cells, which may be of critical importance for clinical use, especially when the number of starting antigen-sensitized T cells is limited. This would likely be the case with vaccine-draining lymph nodes, an approach we plan to apply clinically. The comparatively simple regimen described here, with a modest dose of CYP followed by infusion of T cells cultured for short periods of time may be particularly applicable to clinical use. Future experiments will examine more detailed comparisons of the functions, phenotypes and fates after adoptive transfer of cells grown in IL-7/15 versus those grown in IL-2.
